Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 88

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Inclusion body myositis

Not recruiting

Title: Long-term safety and effectiveness study of ulviprubart in patients with inclusion body myositis who completed previous treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ulviprubart
  • Sponsor:Abcuro Inc.

Conjunctivitis allergic+1

Not recruiting

Study of CLU-RX-BET injection therapy for patients with moderate to severe birch pollen allergies

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Birch pollen allergoid glutaraldehyde modified
  • Sponsor:ROXALL Medizin GmbH

Coeliac disease

Not recruiting

Study of TEV-53408 Safety and Effectiveness in Adults with Celiac Disease During Gluten Exposure

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:TEV-53408
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Hereditary angioedema

Not recruiting

Study on the Effect and Safety of BW-20805 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BW-20805
  • Sponsor:Shanghai Argo Biopharmaceutical Co. Ltd.

VEXAS syndrome

Not recruiting

Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Sobi Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Type 1 diabetes mellitus+1

Not recruiting

Study on the Effectiveness and Safety of Finerenone for Patients with Chronic Kidney Disease and Type 1 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Long-term Safety of Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Cerebral amyloid angiopathy

Not recruiting

Study on the Safety and Effects of ALN-APP for Patients with Cerebral Amyloid Angiopathy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ALN-961583
  • Sponsor:Alnylam Pharmaceuticals Inc.

Interstitial lung disease+1

Not recruiting

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
  • Sponsor:Boehringer Ingelheim Espana S.A.

Conjunctivitis allergic+1

Not recruiting

Study on the Safety and Effectiveness of Subcutaneous Immunotherapy with Der p 1, Der p 2, and Der p 23 Allergens for Patients with Allergic Rhinitis or Rhinoconjunctivitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dermatophagoides Pteronyssinus
  • Sponsor:Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.

Conjunctivitis allergic+1

Not recruiting

Study on the Effectiveness and Safety of CLU-RX-DPT for Patients with Moderate-to-Severe House Dust Mite Allergy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dermatophagoides Pteronyssinus Allergoid, Glutaraldehyde-Modified
  • Sponsor:ROXALL Medizin GmbH

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.